{"id":746046,"date":"2019-05-08T08:00:00","date_gmt":"2019-05-08T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/"},"modified":"2025-05-12T08:58:08","modified_gmt":"2025-05-12T12:58:08","slug":"merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/","title":{"rendered":"Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants"},"content":{"rendered":"<p class=\"bwalignc\">       V114 Met Primary Endpoint by Demonstrating Noninferiority to PCV13        for all Shared Serotypes, and an Immune Response for Two Additional        Serotypes     <\/p>\n<p class=\"bwalignc\">       Data Support Continued Progression of Phase 3 Studies with V114     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced results from a Phase 2 trial (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02987972?term=V114&amp;rank=3\" rel=\"nofollow\">NCT02982972<\/a><br \/>\n<span class=\"bwuline\">)<\/span><br \/>\n      evaluating the safety, tolerability and immunogenicity of V114, the<br \/>\n      company\u2019s investigational 15-valent pneumococcal conjugate vaccine, as<br \/>\n      compared to the currently available 13-valent pneumococcal conjugate<br \/>\n      vaccine (PCV13) in healthy infants 6-12 weeks of age. In the study,<br \/>\n      designated V114-008, V114 met its primary endpoint by demonstrating<br \/>\n      noninferiority for the 13 serotypes contained in both vaccines. V114<br \/>\n      also induced an immune response in infants for two additional<br \/>\n      disease-causing serotypes, 22F and 33F, which are not contained in<br \/>\n      PCV13. In January 2019, V114 received a Breakthrough Therapy Designation<br \/>\n      from the U.S. Food and Drug Administration (FDA) for the prevention of<br \/>\n      invasive pneumococcal disease (IPD) caused by the vaccine serotypes in<br \/>\n      pediatric patients 6 weeks to 18 years of age. The FDA\u2019s decision was<br \/>\n      informed in part by immunogenicity data from this Phase 2 study,<br \/>\n      V114-008, and the Phase 1\/2 V114-005 study in healthy adults and<br \/>\n      infants. Results of the V114-008 study were presented during an oral<br \/>\n      session at the 37<sup>th<\/sup> Annual Meeting of the European Society<br \/>\n      for Paediatric Infectious Diseases (ESPID) in Ljubljana, Slovenia, and<br \/>\n      reinforce continued progression of Phase 3 clinical studies with V114.\n    <\/p>\n<p>\n      \u201cChildren under the age of two are at increased risk for pneumococcal<br \/>\n      infection, which in some cases may lead to serious illnesses like<br \/>\n      pneumococcal pneumonia,\u201d said Dr. David Greenberg, study investigator<br \/>\n      and physician in the Pediatric Infectious Disease Unit of Soroka<br \/>\n      University Medical Center in Beer-Sheva, Israel. \u201cThese Phase 2 data<br \/>\n      evaluating V114 in infants are encouraging and mark important progress<br \/>\n      to helping expand protection against pneumococcal disease for this<br \/>\n      vulnerable patient population.\u201d\n    <\/p>\n<p>\n      V114-008, a double-blind, randomized, Phase 2 trial, compared the<br \/>\n      safety, tolerability, and immunogenicity of two different clinical lots<br \/>\n      of V114 (n=350 for lot 1; n=347 for lot 2) to PCV13 (n=347) in<br \/>\n      approximately 1,050 healthy infants at two, four, six and 12-15 months<br \/>\n      of age. In the study, the percentage of subjects who achieved the<br \/>\n      WHO-accepted threshold of immune response (IgG\u22650.35 mcg\/mL) with either<br \/>\n      lot of V114 was noninferior to the percentage seen with PCV13 for the 13<br \/>\n      serotypes shared between the two vaccines. For serotype 3, the<br \/>\n      percentage of subjects who achieved this threshold of immune response<br \/>\n      was higher for V114 (96.0% for lot 1; 94.1% for lot 2) compared with<br \/>\n      PCV13 (71.8%). For the two serotypes not included in PCV13, serotype 22F<br \/>\n      and serotype 33F, the percentage of subjects who achieved the defined<br \/>\n      threshold of immune response with V114 was above 98% (98.9% for lot 1;<br \/>\n      98.5% for lot 2) and above 87% (87.7% for lot 1; 90.1% for lot 2),<br \/>\n      respectively. Results were consistent between the two lots of V114<br \/>\n      studied.\n    <\/p>\n<p>\n      Safety profiles were evaluated after each dose and throughout the study.<br \/>\n      In the study, the adverse event profile for V114, including the number<br \/>\n      of serious adverse events (AEs), was found to be comparable to PCV13.<br \/>\n      The percentage of subjects who reported clinical AEs and serious AEs was<br \/>\n      similar in all treatment arms. The most commonly reported adverse events<br \/>\n      were injection site reactions, the majority of which were mild to<br \/>\n      moderate in severity and of short duration.\n    <\/p>\n<p>\n      \u201cThese new data for our investigational pneumococcal disease vaccine<br \/>\n      V114 build on Merck\u2019s century-long heritage in vaccines and our<br \/>\n      commitment to improving global health through protection from infectious<br \/>\n      diseases,\u201d said Dr. Nicholas Kartsonis, senior vice president and head<br \/>\n      of vaccine and infectious diseases clinical research at Merck Research<br \/>\n      Laboratories. \u201cWe are deeply committed to advancing compounds such as<br \/>\n      V114 that have the potential to make a meaningful impact on the burden<br \/>\n      of pneumococcal disease.\u201d\n    <\/p>\n<p>\n      Merck has a broad clinical development program for V114 currently<br \/>\n      comprised of 11 Phase 3 clinical trials. These studies are investigating<br \/>\n      V114 in adults (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03480763?term=V114&amp;phase=2&amp;rank=7\" rel=\"nofollow\">NCT03480763<\/a>,<br \/>\n      <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03615482?term=V114&amp;phase=2&amp;rank=6\" rel=\"nofollow\">NCT03615482<\/a>),<br \/>\n      in the pediatric population (<a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03692871?cond=NCT03692871&amp;rank=1\" rel=\"nofollow\">NCT03692871<\/a>,<br \/>\n      <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03620162?term=V114&amp;phase=2&amp;rank=10\" rel=\"nofollow\">NCT03620162<\/a>,<br \/>\n      <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03885934?cond=V114-024&amp;rank=1\" rel=\"nofollow\">NCT03885934<\/a>,<br \/>\n      <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03893448?term=V114&amp;draw=2&amp;rank=17\" rel=\"nofollow\">NCT03893448<\/a>),<br \/>\n      and in immunocompromised persons and those at increased risk for<br \/>\n      invasive pneumococcal disease (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03547167?term=V114&amp;draw=2&amp;rank=12\" rel=\"nofollow\">NCT03547167<\/a>,<br \/>\n      <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03921424?term=V114&amp;draw=2&amp;rank=5\" rel=\"nofollow\">NCT03921424<\/a>,<br \/>\n      <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03731182?term=V114&amp;draw=2&amp;rank=1\" rel=\"nofollow\">NCT03731182<\/a>,<br \/>\n      <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03480802?term=V114&amp;rank=8\" rel=\"nofollow\">NCT03480802<\/a>,<br \/>\n      <a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03565900?cond=V114-022&amp;rank=1\" rel=\"nofollow\">NCT03565900<\/a>).\n    <\/p>\n<p>\n      <b>Additional Detail About V114-008 Study Design<\/b>\n    <\/p>\n<p>\n      In the V114-008 study, immunogenicity results were described as the<br \/>\n      percentage of subjects who reached an internationally accepted threshold<br \/>\n      of immune response considered to be protective (IgG\u22650.35 mcg\/mL). The<br \/>\n      primary immunogenicity endpoint was to demonstrate that V114 was<br \/>\n      noninferior to PCV13 based on the proportion of infants achieving<br \/>\n      serotype-specific IgG\u22650.35 mcg\/mL for all 13 serotypes in common with<br \/>\n      PCV13 at one-month following the completion of the three dose primary<br \/>\n      series. Additionally, serotype-specific IgG geometric mean<br \/>\n      concentrations (GMCs) were measured at one month following the<br \/>\n      completion of the primary series, immediately prior to the toddler dose<br \/>\n      and one month after the toddler dose.\n    <\/p>\n<p>\n      <b>About V114<\/b>\n    <\/p>\n<p>\n      V114 is Merck\u2019s investigational 15-valent pneumococcal conjugate vaccine<br \/>\n      in Phase 3 development for the prevention of pneumococcal disease in<br \/>\n      adults and children. V114 consists of pneumococcal polysaccharides from<br \/>\n      15 serotypes conjugated to a CRM197 carrier protein, and includes<br \/>\n      serotypes 22F and 33F, which are commonly associated with IPD worldwide.\n    <\/p>\n<p>\n      <b>About Pneumococcal Disease<\/b>\n    <\/p>\n<p>\n      Pneumococcal disease is an infection caused by bacteria called <i>Streptococcus<br \/>\n      pneumoniae.<\/i> Pneumococcal disease includes non-invasive illnesses<br \/>\n      such as pneumonia (when it is confined to the lungs), sinusitis, and<br \/>\n      otitis media (middle ear infection); and invasive illnesses such as<br \/>\n      bacteremia (infection in the bloodstream), bacteremic pneumonia<br \/>\n      (pneumonia with bacteremia), and meningitis. While healthy adults and<br \/>\n      children are at risk for pneumococcal disease, patient populations<br \/>\n      particularly vulnerable to infection include children under the age of<br \/>\n      2, adults aged 65 and older, and people with immunosuppressive or<br \/>\n      chronic health conditions.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to Infectious Diseases<\/b>\n    <\/p>\n<p>\n      For more than 100 years, Merck has contributed to the discovery and<br \/>\n      development of novel medicines and vaccines to combat infectious<br \/>\n      diseases. In addition to a combined portfolio of vaccines and<br \/>\n      antibacterial, antiviral and antifungal medicines, Merck has multiple<br \/>\n      programs that span discovery through late-stage development. To learn<br \/>\n      more about Merck\u2019s infectious diseases pipeline, visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele<br \/>(267) 305-3558<\/p>\n<p>Kristen Drake<br \/>(908)        740-6179<\/p>\n<p>Investors:<br \/>Teri Loxam<br \/>(908) 740-1986<\/p>\n<p>Michael        DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a Phase 2 trial ( NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114, the company\u2019s investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age. In the study, designated V114-008, V114 met its primary endpoint by demonstrating noninferiority for the 13 serotypes contained in both vaccines. V114 also induced an immune response in infants for two additional disease-causing serotypes, 22F and 33F, which are not contained in PCV13. In January 2019, V114 received a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age. The FDA\u2019s decision was informed in part by immunogenicity<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-746046","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a Phase 2 trial ( NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114, the company\u2019s investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age. In the study, designated V114-008, V114 met its primary endpoint by demonstrating noninferiority for the 13 serotypes contained in both vaccines. V114 also induced an immune response in infants for two additional disease-causing serotypes, 22F and 33F, which are not contained in PCV13. In January 2019, V114 received a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age. The FDA\u2019s decision was informed in part by immunogenicity\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\\\/\",\"name\":\"Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-05-08T08:00:00+00:00\",\"dateModified\":\"2025-05-12T12:58:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a Phase 2 trial ( NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114, the company\u2019s investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age. In the study, designated V114-008, V114 met its primary endpoint by demonstrating noninferiority for the 13 serotypes contained in both vaccines. V114 also induced an immune response in infants for two additional disease-causing serotypes, 22F and 33F, which are not contained in PCV13. In January 2019, V114 received a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age. The FDA\u2019s decision was informed in part by immunogenicity","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:08+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/","name":"Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-05-08T08:00:00+00:00","dateModified":"2025-05-12T12:58:08+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-trial-of-investigational-15-valent-pneumococcal-conjugate-vaccine-v114-in-infants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fa9b0d4e-ec6d-427b-8335-4e03c39ecfdc","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Results-from-Phase-2-Trial-of-Investigational-15-valent-Pneumococcal-Conjugate-Vaccine-V114-in-Infants-2019.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746046\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746046"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}